(NASDAQ:NTRA) AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided an update regarding its intellectual property litigation with NeoGenomics, Inc. The U.S. District Court for the Middle District of North Carolina issued a ruling invalidating certain claims in two patents that Natera asserted against NeoGenomics’ v1.1 RaDaR test. Natera is evaluating its options, including an appeal and further enforcement with other patents. Impo
Related Questions
How might the invalidation of these patent claims affect Natera's revenue projections and cash flow in the next quarters?
What are the potential market reactions to an appeal or further enforcement actions, and how could this influence NTRA's stock volatility?
How does this litigation outcome compare to recent IP disputes involving other precision medicine companies, and what implications does it have for Natera's competitive positioning?